These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20727068)

  • 1. Coagulation factor XI as a novel target for antithrombotic treatment.
    Löwenberg EC; Meijers JC; Monia BP; Levi M
    J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Zhang H; Löwenberg EC; Crosby JR; MacLeod AR; Zhao C; Gao D; Black C; Revenko AS; Meijers JC; Stroes ES; Levi M; Monia BP
    Blood; 2010 Nov; 116(22):4684-92. PubMed ID: 20807891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.
    Crosby JR; Marzec U; Revenko AS; Zhao C; Gao D; Matafonov A; Gailani D; MacLeod AR; Tucker EI; Gruber A; Hanson SR; Monia BP
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1670-8. PubMed ID: 23559626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
    Vlădăreanu AM; Roşca A
    Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hemostatic role of factor XI.
    Puy C; Rigg RA; McCarty OJ
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital factor XI deficiency: an update.
    Duga S; Salomon O
    Semin Thromb Hemost; 2013 Sep; 39(6):621-31. PubMed ID: 23929304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.
    Visser M; van Oerle R; Ten Cate H; Laux V; Mackman N; Heitmeier S; Spronk HMH
    Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):103-111. PubMed ID: 31766871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis.
    Zhong C; Zhang L; Chen L; Deng L; Li R
    J Thromb Haemost; 2017 Jan; 15(1):122-130. PubMed ID: 27813324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor XI: hemostasis, thrombosis, and antithrombosis.
    He R; Chen D; He S
    Thromb Res; 2012 May; 129(5):541-50. PubMed ID: 22197449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model.
    van Montfoort ML; Knaup VL; Marquart JA; Bakhtiari K; Castellino FJ; Hack CE; Meijers JC
    Thromb Haemost; 2013 Nov; 110(5):1065-73. PubMed ID: 23925504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting factor XI and factor XIa to prevent thrombosis.
    Gailani D; Gruber A
    Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic pathway of coagulation and arterial thrombosis.
    Gailani D; Renné T
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
    J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein.
    Ay C; Hisada Y; Cooley BC; Mackman N
    J Thromb Haemost; 2017 Sep; 15(9):1829-1833. PubMed ID: 28677246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor XI and XII as antithrombotic targets.
    Müller F; Gailani D; Renné T
    Curr Opin Hematol; 2011 Sep; 18(5):349-55. PubMed ID: 21730835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
    Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
    N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants.
    Weitz JI; Fredenburgh JC
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):304-310. PubMed ID: 29269514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
    Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.